2022-2029 年全球去勢抵抗性前列腺癌治療市場
市場調查報告書
商品編碼
1140679

2022-2029 年全球去勢抵抗性前列腺癌治療市場

Global Castrate Resistant Prostate Cancer Therapeutics Market - 2022-2029

出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

前列腺癌患病率上升導致市場增長。

全球前列腺癌患病率的上升正在刺激前列腺癌藥物的市場增長。前列腺癌是男性最常見的癌症,除了皮膚癌。根據 Cancer.Net 編輯委員會的估計數據,2022 年美國將有 268,490 名男性被診斷出患有前列腺癌。網絡編輯委員會估計顯示,2020 年將有 1,414,259 名男性被診斷出患有前列腺癌。它是世界上第四大最常見的癌症。它是美國男性癌症死亡的第二大原因。 2020年將有34,500人死於前列腺癌,全球將有375,304人死於前列腺癌。發達國家的前列腺癌患病率高於發展中國家。癌症患者數量的增加將導致對去勢抵抗性前列腺癌藥物的需求增加,以最大限度地降低死亡風險並減少病毒對腫瘤的影響。全球市場的消費者俱有健康意識,願意花大價錢改善嚴重的健康狀況。在預測期內,消費者平均消費能力的提高和癌症患病率的上升將推動全球對去勢抵抗性前列腺癌治療的需求。

幾種針對去勢抵抗性前列腺癌的藥物獲批將有助於市場增長。政府對去勢抵抗性前列腺癌藥物營銷的關注在世界範圍內顯著增加。最近的幾項發展突出了去勢抵抗性前列腺癌治療市場,包括: 2022 年 3 月,FDA 批准 Pullvict 用於通過雄激素受體( AR )通路阻斷和紫杉烷化療治療的轉移性去勢抵抗性前列腺癌。

然而,與去勢抵抗性前列腺癌治療相關的高成本將成為預測期內市場增長的主要抑制因素。

地理滲透。

北美是預測期內的主要地區。

2019年,全球去勢抵抗性前列腺癌治療市場以市場份額最大的北美市場為主。推動北美市場增長的因素包括前列腺癌發病率和患病率的顯著增加以及提高對前列腺癌認識的舉措。例如,美國和加拿大每年 9 月都會慶祝前列腺癌宣傳月。該組織還為前列腺癌研究提供資助。

此外,預計亞太地區將以全球市場最高的複合年增長率增長。這是由於該地區前列腺癌的高發病率以及中國和印度等主要經濟體迅速發展的醫療基礎設施,推動了前列腺癌藥物市場的增長。

競爭格局。

去勢抵抗性前列腺癌治療市場由少數公司主導。主要的市場增長參與者包括 Astellas Pharma、Bayer AG、Johnson & Johnson Services、輝瑞、Sanofi SA、GlaxoSmithKline PLC、Northwest BioTherapy 和 Active Biotech AB。預計主要參與者將執行多項增長戰略,例如產品發布、收購和合作夥伴關係,這些戰略預計將促進全球去勢抵抗性前列腺癌治療市場的增長。 2020年5月,XTANDI獲日本厚生勞動省批准用於治療遠處轉移的前列腺癌。 XTANDI 是一種口服雄激素受體信號抑製劑,適用於治療轉移性前列腺癌患者。 2022 年 8 月,FDA 批准買方的前列腺癌藥物擴大使用。該批准基於 ARASENS 3 期試驗的結果,該試驗表明,與 ADT 和多西他賽相比,Nubeqa 與雄激素剝奪療法和多西他賽相結合可將死於前列腺癌的風險降低多達 32%。一些大公司遵循收購戰略來擴大業務。例如,2021 年 6 月,拜耳收購了 Noria 和 PSMA Therapeutics,以擴大其前列腺癌管道。通過此次收購,買方擁有基於actinium-225和前列腺特異性膜抗原(PSMA)小分子的差異化α-放射性核素研究化合物的獨家權利。

COVID-19 的影響將對全球去勢抵抗性前列腺癌治療市場產生負面影響。

COVID-19 的爆發預計將減緩 2020 年去勢抵抗性前列腺癌治療市場的增長。由於醫院就診次數減少導致的診斷率下降是對 2020 年去勢抵抗性前列腺癌治療市場增長產生負面影響的主要因素。

內容

第 1 章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 按治療類型劃分的市場細分
  • 按給藥方式劃分的市場細分
  • 按地區劃分的市場細分

第 4 章市場動態

  • 市場影響因素
    • 促進因素
      • 去勢抵抗性前列腺癌的患病率不斷上升
      • 醫療保健支出增加
    • 抑制因素
      • 缺乏標準治療
    • 商機
    • 影響分析

第 5 章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 價值鏈分析
  • PEST 分析
  • 定價分析
  • 監管分析
  • 保險報銷分析
  • 未滿足的需求
  • 專利趨勢

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按治療類型

  • 化療
  • 激素療法
  • 免疫療法
  • 放射治療

第 8 章給藥方式

  • 口服
  • 注入

第 9 章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 10 章競爭格局

  • 競爭場景
  • 市場定位/市場份額分析
  • 併購分析

第 11 章公司簡介

  • Astellas Pharma, Inc.
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Bayer AG
  • Johnson & Johnson Services Inc.
  • Pfizer Inc.
  • Sanofi SA
  • GlaxoSmithKline PLC
  • Northwest Biotherapeutic
  • Active Biotech AB
  • Spectrum Pharmaceuticals
  • Abbott Laboratories
  • Other Companies(*LIST NOT EXHAUSTIVE)

第 12 章 DataM

簡介目錄
Product Code: DMHCIT2977

Market Overview

Castrate Resistant Prostate Cancer Therapeutics Market was valued at USD XX million in 2021. It is forecasted to reach USD XX million by 2029, growing at a CAGR of 8.4% during the forecast period (2022-2029).

Castration-resistant prostate cancer is stated as prostate cancer that is scattered to other parts of the body. Several risk factors for castration-resistant prostate cancer include genetic predisposition, unhygienic diet, geriatric population, medication exposure, and many sexual partners. The methods were available to diagnose castration-resistant prostate cancer, including prostate imaging, tumor marker, biopsy, and staging test. For CRPC treatment, docetaxel-based chemotherapy has been widely accepted by urologists and oncologists. The increasing prevalence of prostate cancer, including castration-resistant prostate cancer, augments the market growth. Moreover, the increasing geriatric population is the main driver of the market.

Market Dynamics: The growing prevalence of prostate cancer leads to the market's growth.

The rising incidences of prostate cancer globally are spurring the market growth for prostate cancer therapeutics. Prostate cancer is most common in men, except for skin cancer. According to the data estimated by the Cancer.Net Editorial Board, 268,490 men in the United States were diagnosed with prostate cancer in 2022. According to Net Editorial Board, estimated data of 1,414,259 people were diagnosed with prostate cancer in 2020. It is the fourth most commonly diagnosed cancer in the world. It is the second leading cause of cancer death in men in the United States. There were 34,500 people who died of prostate cancer in 2020, and 375,304 people worldwide died of prostate cancer. Developed nations have a higher prevalence of prostate cancer cases than developing nations. Cancer patients' growth leads to increased demand for castrate-resistant prostate cancer therapeutics to minimize the risk of death and lower the virus's effect on the tumor. The global market consumers are highly health-conscious and ready to spend high amounts to enhance their severe health conditions. The growth in the consumers' average purchasing power and rising cancer prevalence will fuel the demand for castrate-resistant prostate cancer therapeutics globally during the forecast period.

Several drug approvals for castrate-resistant prostate cancer help to grow market growth. The government's focus on marketing castrate-resistant prostate cancer therapeutics is increasing considerably across the globe. There are several recent developments noticed in the castrate-resistant prostate cancer therapeutics market, such as. In March 2022, the FDA approved Pluvicto for metastatic castration-resistant prostate cancer treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.

However, the high cost associated with castrate-resistant prostate cancer treatment is the major restraint for the market's growth during the forecast period.

Market Segmentation: The oral drug delivery segment accounted for the highest share in global castrate resistant prostate cancer therapeutics market.

The castrate-resistant prostate cancer therapeutics market is classified into oral drug delivery methods and injectable drug delivery methods by drug delivery method. The oral drug delivery method contributes a major share of the castrate-resistant prostate cancer therapeutics market. The doctors majorly suggest oral medicines compared to injectables for the treatment of castrate-resistant prostate cancer. The market players have also engaged in marketing oral castrate-resistant prostate cancer therapeutics across the globe.

By therapy type, the castrate-resistant prostate cancer therapeutics market is classified into chemotherapy, hormonal therapy, immunotherapy, and radiotherapy. The hormonal therapy segment held a significant share in the market. Hormone therapy is often regarded as an androgen suppression therapy. The therapy aims to block or lower testosterone in the body to stop it from fueling prostate cancer cells' growth. Lowering androgen levels often makes prostate cancers grow sluggish. Based on drugs' functioning, hormonal therapy is of different types that include orchiectomy and medical castration. Medical castration involves the luteinizing hormone-releasing hormone (LHRH) agonist drugs that lower the amount of testosterone made by the testicles. Leuprolide, Goserelin, Triptorelin, and Histrelin are the commonly used LHRH agonist drugs available in the US market.

Geographical Penetration: North America is the dominating region during the forecast period.

The North American market dominated with the largest market share in the global castrate-resistant prostate cancer therapeutics market in 2019. Factors augmenting the North American market's growth include a significant rise in the incidence and prevalence of prostate cancer and initiatives to create awareness for prostate cancer. For instance, Prostate Cancer Awareness Month is observed in the US and Canada in September every year. Also, the organizations offer grants for prostate cancer research.

Moreover, the Asia Pacific region is expected to grow at the highest CAGR in the global market owing to the high prevalence of prostate cancer in the region coupled with the rapidly evolving healthcare infrastructure in major economies such as China and India are fueling the growth of the castrate-resistant prostate cancer therapeutics market.

Competitive Landscape:

The castrate-resistant prostate cancer therapeutics market is dominated by a few companies. Some of the key players in the market's growth include Astellas Pharma, Inc., Bayer AG, Johnson & Johnson Services Inc., Pfizer Inc., Sanofi SA, GlaxoSmithKline PLC, Northwest Biotherapeutic, and Active Biotech AB, among others. The key players execute several growth strategies, such as product launches, acquisitions, and collaborations, which are estimated to boost the castrate-resistant prostate cancer therapeutics market growth globally. In May 2020, XTANDI was approved by the Japan Ministry of Health, Labour and Welfare (MHLW), which is used for the treatment of prostate cancer with distant metastasis. XTANDI is the oral androgen receptor signaling inhibitor for the treatment of prostate cancer patients with distant metastasis. In August 2022, FDA approved the expanded use of Buyer's prostate cancer drug. This approval is based on the results of Phase 3 ARASENS trial, which demonstrated a reduction in the risk of death by prostate cancer up to 32% in Nubeqa plus androgen deprivation therapy and docetaxel compared to ADT and docetaxel. Some major players follow acquisition strategies to expand their business. For instance, in June 2021, Bayer Acquired Noria and PSMA Therapeutics to expand its pipeline in prostate cancer. Through this acquisition, the Buyer obtained exclusive rights to a differentiated alpha radionuclide investigational compound based on actinium-225 and a small molecule directed towards prostate-specific membrane antigen (PSMA).

COVID-19 Impact: Negative impact on the global castrate resistant prostate cancer therapeutics market.

The COVID-19 pandemic outbreak is expected to derail the growth of the castrate-resistant prostate cancer therapeutics market in 2020. The decline in the diagnosis rate due to the downfall in the number of hospital visits is the major factor that has negatively impacted the castrate-resistant prostate cancer therapeutics market growth in 2020.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Therapy Type
  • 3.2. Market Snippet by Drug Delivery Method
  • 3.3. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising prevalence of castrate-resistant prostate cancer
      • 4.1.1.2. Increasing spending on healthcare
    • 4.1.2. Restraints:
      • 4.1.2.1. Lack of standard therapy
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Value Chain Analysis
  • 5.4. PEST Analysis
  • 5.5. Pricing Analysis
  • 5.6. Regulatory Analysis
  • 5.7. Reimbursement Analysis
  • 5.8. Unmet Needs
  • 5.9. Patent Trends

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Therapy Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type Segment.
  • 7.3. Market Attractiveness Index, By Therapy Type Segment
    • 7.3.1. Chemotherapy
      • 7.3.1.1. Introduction
      • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Hormonal Therapy
    • 7.3.3. Immunotherapy
    • 7.3.4. Radiotherapy

8. By Drug Delivery Method

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Delivery Method Segment.
  • 8.3. Market Attractiveness Index, By Drug Delivery Method Segment
    • 8.3.1. Oral
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Injectable

9. By Region

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 9.3. Market Attractiveness Index, By Region
  • 9.4. North America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Delivery Method
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.5.1. The U.S.
      • 9.4.5.2. Canada
      • 9.4.5.3. Mexico
  • 9.5. Europe
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Delivery Method
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.5.1. Germany
      • 9.5.5.2. The U.K.
      • 9.5.5.3. France
      • 9.5.5.4. Italy
      • 9.5.5.5. Spain
      • 9.5.5.6. Rest of Europe
  • 9.6. South America
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Delivery Method
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.6.5.1. Brazil
      • 9.6.5.2. Argentina
      • 9.6.5.3. Rest of South America
  • 9.7. Asia Pacific
    • 9.7.1. Introduction
    • 9.7.2. Key Region-Specific Dynamics
    • 9.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
    • 9.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Delivery Method
    • 9.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.7.5.1. China
      • 9.7.5.2. India
      • 9.7.5.3. Japan
      • 9.7.5.4. Australia
      • 9.7.5.5. Rest of Asia Pacific
  • 9.8. The Middle East and Africa
    • 9.8.1. Introduction
    • 9.8.2. Key Region-Specific Dynamics
    • 9.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy Type
    • 9.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Delivery Method
    • 9.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Astellas Pharma, Inc.*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Bayer AG
  • 11.3. Johnson & Johnson Services Inc.
  • 11.4. Pfizer Inc.
  • 11.5. Sanofi SA
  • 11.6. GlaxoSmithKline PLC
  • 11.7. Northwest Biotherapeutic
  • 11.8. Active Biotech AB
  • 11.9. Spectrum Pharmaceuticals
  • 11.10. Abbott Laboratories
  • 11.11. Other Companies(*LIST NOT EXHAUSTIVE)

12. DataM Intelligence

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us